Drug intelligence / Profile preview

SKI-II

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

SKI-II is a selective non-lipid inhibitor of sphingosine kinase (SK) with an IC50 of 0.5 μM. It does not act at the ATP-binding site and does not inhibit ERK2, PI3K, or PKCα. SKI-II induces apoptosis and inhibits proliferation in several tumor cell lines, displaying potential as an antitumor agent.

Other names: 2-(p-Hydroxyanilino)-4-(p-chlorophenyl)thiazole

Targets

DEGS1 (Delta(4)-desaturase, sphingolipid 1)SPHK1 (Sphingosine kinase 1)SPHK2 (Sphingosine kinase 2)

Beyond the preview

Go deeper on SKI-II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKI-II.

Explore the full profile